ENTO
Vanguard Group’s Entero Therapeutics ENTO Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-16,478
| Closed | -$4.78K | – | 4517 |
|
|
2023
Q3 | $4.78K | Buy |
16,478
+1
| +0% | – | ﹤0.01% | 4529 |
|
|
2023
Q2 | $26.4K | Buy |
+16,477
| New | +$26.4K | ﹤0.01% | 4504 |
|
|
2022
Q2 | – | Sell |
-214,553
| Closed | -$227K | – | 4641 |
|
|
2022
Q1 | $227K | Sell |
214,553
-78,451
| -27% | -$83K | ﹤0.01% | 4518 |
|
|
2021
Q4 | $424K | Sell |
293,004
-592
| -0.2% | -$857 | ﹤0.01% | 4455 |
|
|
2021
Q3 | $825K | Sell |
293,596
-2,630,492
| -90% | -$7.39M | ﹤0.01% | 4287 |
|
|
2021
Q2 | $2.4M | Buy |
2,924,088
+1,848,604
| +172% | +$1.52M | ﹤0.01% | 3916 |
|
|
2021
Q1 | $1.44M | Buy |
1,075,484
+389,562
| +57% | +$522K | ﹤0.01% | 3932 |
|
|
2020
Q4 | $665K | Sell |
685,922
-46,210
| -6% | -$44.8K | ﹤0.01% | 3913 |
|
|
2020
Q3 | $521K | Buy |
732,132
+44,968
| +7% | +$32K | ﹤0.01% | 3805 |
|
|
2020
Q2 | $623K | Sell |
687,164
-11,374
| -2% | -$10.3K | ﹤0.01% | 3716 |
|
|
2020
Q1 | $405K | Hold |
698,538
| – | – | ﹤0.01% | 3716 |
|
|
2019
Q4 | $726K | Hold |
698,538
| – | – | ﹤0.01% | 3710 |
|
|
2019
Q3 | $419K | Buy |
698,538
+438,232
| +168% | +$263K | ﹤0.01% | 3851 |
|
|
2019
Q2 | $443K | Buy |
260,306
+186,985
| +255% | +$318K | ﹤0.01% | 3847 |
|
|
2019
Q1 | $177K | Hold |
73,321
| – | – | ﹤0.01% | 3946 |
|
|
2018
Q4 | $89K | Sell |
73,321
-340,118
| -82% | -$413K | ﹤0.01% | 4009 |
|
|
2018
Q3 | $1.06M | Buy |
413,439
+8,489
| +2% | +$21.8K | ﹤0.01% | 3703 |
|
|
2018
Q2 | $1.3M | Buy |
404,950
+291,366
| +257% | +$935K | ﹤0.01% | 3618 |
|
|
2018
Q1 | $357K | Buy |
113,584
+24,306
| +27% | +$76.4K | ﹤0.01% | 3854 |
|
|
2017
Q4 | $330K | Buy |
89,278
+7,145
| +9% | +$26.4K | ﹤0.01% | 3839 |
|
|
2017
Q3 | $328K | Buy |
+82,133
| New | +$328K | ﹤0.01% | 3827 |
|